Brainstorm Cell Therapeutics annual debt-to-assets ratio
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Brainstorm Cell Therapeutics Debt-to-Assets Ratio Growth & History (BCLI)
Brainstorm Cell Therapeutics's debt-to-assets ratio was 1.15 for fiscal 2025.
View full Brainstorm Cell Therapeutics company overviewBrainstorm Cell Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.15 | 0.59 | +106.50% |
| 2024 | 2024-12-31 | 0.56 | 0.25 | +83.76% |
| 2023 | 2023-12-31 | 0.30 | −0.18 | −37.44% |
| 2022 | 2022-12-31 | 0.48 | 0.31 | +179.18% |
| 2021 | 2021-12-31 | 0.17 | 0.03 | +23.22% |
| 2020 | 2020-12-31 | 0.14 | −0.22 | −61.12% |
| 2019 | 2019-12-31 | 0.36 | 0.36 | — |
| 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| 2014 | 2014-12-31 | 0.00 | 0.00 | — |
| 2013 | 2013-12-31 | 0.00 | 0.00 | — |
| 2012 | 2012-12-31 | 0.00 | 0.00 | — |
| 2011 | 2011-12-31 | 0.00 | −0.13 | — |
| 2010 | 2010-12-31 | 0.13 | — | — |
Brainstorm Cell Therapeutics quarterly debt-to-assets ratio
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.74 | 1.52 | +675.43% |
| Q1 2026 | 2026-03-31 | 1.97 | 1.48 | +297.62% |
| Q4 2025 | 2025-12-31 | 1.15 | 0.59 | +106.50% |
| Q3 2025 | 2025-09-30 | 0.31 | −0.11 | −25.50% |
| Q2 2025 | 2025-06-30 | 0.22 | 0.06 | +32.84% |
| Q1 2025 | 2025-03-31 | 0.50 | 0.16 | +48.03% |
| Q4 2024 | 2024-12-31 | 0.56 | 0.25 | +83.76% |
| Q3 2024 | 2024-09-30 | 0.42 | −0.09 | −18.37% |
| Q2 2024 | 2024-06-30 | 0.17 | −0.40 | −70.45% |
| Q1 2024 | 2024-03-31 | 0.33 | −0.13 | −28.36% |
| Q4 2023 | 2023-12-31 | 0.30 | −0.18 | −37.44% |
| Q3 2023 | 2023-09-30 | 0.51 | 0.18 | +54.03% |
| Q2 2023 | 2023-06-30 | 0.57 | 0.32 | +129.04% |
| Q1 2023 | 2023-03-31 | 0.47 | 0.25 | +116.75% |
| Q4 2022 | 2022-12-31 | 0.48 | 0.31 | +179.18% |
| Q3 2022 | 2022-09-30 | 0.33 | 0.17 | +107.39% |
| Q2 2022 | 2022-06-30 | 0.25 | 0.11 | +74.85% |
| Q1 2022 | 2022-03-31 | 0.22 | 0.08 | +61.67% |
| Q4 2021 | 2021-12-31 | 0.17 | 0.03 | +23.22% |
| Q3 2021 | 2021-09-30 | 0.16 | 0.11 | +247.12% |
| Q2 2021 | 2021-06-30 | 0.14 | 0.05 | +54.19% |
| Q1 2021 | 2021-03-31 | 0.13 | 0.02 | +19.55% |
| Q4 2020 | 2020-12-31 | 0.14 | −0.22 | −61.12% |
| Q3 2020 | 2020-09-30 | 0.05 | −0.29 | −86.37% |
| Q2 2020 | 2020-06-30 | 0.09 | −0.23 | −71.02% |
| Q1 2020 | 2020-03-31 | 0.11 | −0.15 | −56.58% |
| Q4 2019 | 2019-12-31 | 0.36 | 0.36 | — |
| Q3 2019 | 2019-09-30 | 0.34 | 0.34 | — |
| Q2 2019 | 2019-06-30 | 0.32 | 0.32 | — |
| Q1 2019 | 2019-03-31 | 0.26 | 0.26 | — |
| Q4 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| Q3 2018 | 2018-09-30 | 0.00 | 0.00 | — |
| Q2 2018 | 2018-06-30 | 0.00 | 0.00 | — |
| Q1 2018 | 2018-03-31 | 0.00 | 0.00 | — |
| Q4 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| Q3 2017 | 2017-09-30 | 0.00 | 0.00 | — |
| Q2 2017 | 2017-06-30 | 0.00 | 0.00 | — |
| Q1 2017 | 2017-03-31 | 0.00 | 0.00 | — |
| Q4 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| Q3 2016 | 2016-09-30 | 0.00 | 0.00 | — |
| Q2 2016 | 2016-06-30 | 0.00 | 0.00 | — |
| Q1 2016 | 2016-03-31 | 0.00 | 0.00 | — |
| Q4 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| Q3 2015 | 2015-09-30 | 0.00 | 0.00 | — |
| Q2 2015 | 2015-06-30 | 0.00 | 0.00 | — |
| Q1 2015 | 2015-03-31 | 0.00 | 0.00 | — |
| Q4 2014 | 2014-12-31 | 0.00 | 0.00 | — |
| Q3 2014 | 2014-09-30 | 0.00 | 0.00 | — |
| Q2 2014 | 2014-06-30 | 0.00 | 0.00 | — |
| Q1 2014 | 2014-03-31 | 0.00 | 0.00 | — |
| Q4 2013 | 2013-12-31 | 0.00 | 0.00 | — |
| Q3 2013 | 2013-09-30 | 0.00 | 0.00 | — |
| Q2 2013 | 2013-06-30 | 0.00 | 0.00 | — |
| Q1 2013 | 2013-03-31 | 0.00 | 0.00 | — |
| Q4 2012 | 2012-12-31 | 0.00 | 0.00 | — |
| Q3 2012 | 2012-09-30 | 0.00 | 0.00 | — |
| Q2 2012 | 2012-06-30 | 0.00 | 0.00 | — |
| Q1 2012 | 2012-03-31 | 0.00 | — | — |
| Q4 2011 | 2011-12-31 | 0.00 | −0.13 | — |
| Q3 2011 | 2011-09-30 | 0.00 | — | — |
| Q2 2011 | 2011-06-30 | 0.00 | — | — |
| Q4 2010 | 2010-12-31 | 0.13 | — | — |
Brainstorm Cell Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Brainstorm Cell Therapeutics's debt-to-assets ratio increased from 0.14 to 1.15, a change of 1.01. The latest reported quarter, Q2 2026, shows 1.74.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Brainstorm Cell Therapeutics source filings ↗